Cure MSA

Country specific patient information

Innsbruck

Principal Investigators:

Prof. Dr. Werner Poewe
Innsbruck Medical University
Department of Neurology
Anichstrasse 35
6020 Innsbruck, Austria

 

Prof. Dr. Klaus Seppi
Innsbruck Medical University
Department of Neurology
Anichstrasse 35,
A-6020 Innsbruck


Dr. Florian Krismer
Innsbruck Medical University
Department of Neurology
Anichstrasse 35,
A-6020 Innsbruck
Email Contact: office(at)emsa-sg.org

Expertise of the participating organization:


The group has a long time involvement of the clinical assessment and the medical treatment of patients suffering from MSA and other patients with parkinsonism. It is the painful experience of non-responsive and steadily deteriorating MSA patients that drives the Innsbruck group to coordinate the first international collaboration on MSA in order to pave the way towards effective pharmacological intervention in this disorder.
Professor Werner Poewe will coordinate the project from the University Hospital Innsbruck, Professor Gregor Wenning will serve as head of the coordinating office. Professor Werner Poewe has considerable experience with the management of academic concertations. He currently holds the position of president of the Movement Disorders Society (MDS) and coordinates 2 MDS topical task forces. Furthermore, he has coordinated numerous international drug trials. Prof. Gregor Wenning is deeply involved in the care of parkinsonian patients. Since 1992 he has reported clinicopathological features of MSA patients in several important publications. Furthermore, he has designed the first pilot experiments towards a neural transplantation model of MSA.

 

Recent publications relevant to the EMSA-SG:

Sturm E, Fellner L, Krismer F, Poewe W, Wenning GK, Stefanova N. Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. Neurotherapeutics 2016.

 

Scherfler C, Gobel G, Muller C, Nocker M, Wenning GK, Schocke M, Poewe W, Seppi K. Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. Neurology 2016;86:1242-1249.

 

Schafferer S, Khurana R, Refolo V, Venezia S, Sturm E, Piatti P, Hechenberger C, Hackl H, Kessler R, Willi M, Gstir R, Krogsdam A, Lusser A, Poewe W, Wenning GK, Huttenhofer A, Stefanova N. Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. PLoS One 2016;11:e0150705.

 

Krismer F, Seppi K, Wenning GK, Abler V, Papapetropoulos S, Poewe W. Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. Mov Disord 2016.

 

Fanciulli A, Gobel G, Ndayisaba JP, Granata R, Duerr S, Strano S, Colosimo C, Poewe W, Pontieri FE, Wenning GK. Supine hypertension in Parkinson's disease and multiple system atrophy. Clin Auton Res 2016;26:97-105.

 

Reiter E, Mueller C, Pinter B, Krismer F, Scherfler C, Esterhammer R, Kremser C, Schocke M, Wenning GK, Poewe W, Seppi K. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov Disord 2015;30:1068-1076.

 

Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O, Rasagiline-for MSAi. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 2015;14:145-152.

 

Kuzdas-Wood D, Irschick R, Theurl M, Malsch P, Mair N, Mantinger C, Wanschitz J, Klimaschewski L, Poewe W, Stefanova N, Wenning GK. Involvement of Peripheral Nerves in the Transgenic PLP-alpha-Syn Model of Multiple System Atrophy: Extending the Phenotype. PLoS One 2015;10:e0136575.

 

Kaindlstorfer C, Sommer P, Georgievska B, Mather RJ, Kugler AR, Poewe W, Wenning GK, Stefanova N. Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. Neurotox Res 2015;28:185-194.

 

Indelicato E, Fanciulli A, Poewe W, Antonini A, Pontieri FE, Wenning GK. Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2015;21:1393-1397.

 

Wenning GK, Krismer F, Poewe W. Rifampicin for multiple system atrophy. Lancet Neurol 2014;13:237-239.

 

Stankovic I, Krismer F, Jesic A, Antonini A, Benke T, Brown RG, Burn DJ, Holton JL, Kaufmann H, Kostic VS, Ling H, Meissner WG, Poewe W, Semnic M, Seppi K, Takeda A, Weintraub D, Wenning GK, Movement Disorders Society MSASG. Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord 2014;29:857-867.

 

Kuzdas-Wood D, Stefanova N, Jellinger KA, Seppi K, Schlossmacher MG, Poewe W, Wenning GK. Towards translational therapies for multiple system atrophy. Prog Neurobiol 2014;118:19-35.

 

Krismer F, Jellinger KA, Scholz SW, Seppi K, Stefanova N, Antonini A, Poewe W, Wenning GK. Multiple system atrophy as emerging template for accelerated drug discovery in alpha-synucleinopathies. Parkinsonism Relat Disord 2014;20:793-799.

 

Fanciulli A, Strano S, Ndayisaba JP, Goebel G, Gioffre L, Rizzo M, Colosimo C, Caltagirone C, Poewe W, Wenning GK, Pontieri FE. Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. J Neurol 2014;261:1291-1299.

 

Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Kollensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W, European Multiple System Atrophy Study G. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013;12:264-274.

 

Krismer F, Wenning GK, Li Y, Poewe W, Stefanova N. Intact olfaction in a mouse model of multiple system atrophy. PLoS One 2013;8:e64625.

 

Krismer F, Duerr S, Minnerop M, Klockgether T, Stamelou M, Eggert KM, Oertel WH, Schrag A, Poewe W, Wenning GK. [MSA-QoL: disease-specific questionnaire to assess health-related quality of life in multiple system atrophy: validation of the German translation]. Nervenarzt 2013;84:709-714.

 

Wenning GK, Granata R, Krismer F, Durr S, Seppi K, Poewe W, Bleasdale-Barr K, Mathias CJ. Orthostatic hypotension is differentially associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a comparative study. Cerebellum 2012;11:223-226.

 

Stefanova N, Kaufmann WA, Humpel C, Poewe W, Wenning GK. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathol 2012;124:51-65.

 

Stefanova N, Georgievska B, Eriksson H, Poewe W, Wenning GK. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res 2012;21:393-404.

 

Nocker M, Seppi K, Donnemiller E, Virgolini I, Wenning GK, Poewe W, Scherfler C. Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]beta-CIT SPECT. Eur J Nucl Med Mol Imaging 2012;39:1012-1020.

 

Mahlknecht P, Stemberger S, Sprenger F, Rainer J, Hametner E, Kirchmair R, Grabmer C, Scherfler C, Wenning GK, Seppi K, Poewe W, Reindl M. An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. Proteome Sci 2012;10:71.

 

Krismer F, Seppi K, Tison F, Sampaio C, Zangerl A, Peralta C, Yekhlef F, Ghorayeb I, Ory-Magne F, Galitzky M, Bozi M, Scaravilli T, Colosimo C, Geser F, Rascol O, Poewe W, Quinn NP, Wenning GK, European Multiple System Atrophy Study G. The Unified Multiple System Atrophy Rating Scale: intrarater reliability. Mov Disord 2012;27:1683-1685.

 

Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol 2012;11:361-368.

 

Duerr S, Wenning GK, Seppi K, Poewe W. [Atypical Parkinson syndromes--recent advances in diagnosis and therapy]. Fortschr Neurol Psychiatr 2012;80:492-500.

 

Wenning GK, Krismer F, Poewe W. New insights into atypical parkinsonism. Curr Opin Neurol 2011;24:331-338.

 

Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. Toll-like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol 2011;179:954-963.

 

Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK; EMSA-SG.  
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry.  Mov Disord. 2010 Nov 15;25(15):2604-12.

 

Kollensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, et al. Red flags for multiple system atrophy. Mov Disord 2008.

 

Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 2008; 210: 421-7. 

 

Kollensperger M, Seppi K, Liener C, Boesch S, Heute D, Mair KJ, et al. Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 2007; 22: 1771-6. 

 

Kollensperger M, Stampfer-Kountchev M, Seppi K, Geser F, Frick C, Del Sorbo F, et al. Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol 2007; 14: 66-72.

 

Kollensperger M, Stefanova N, Reindl M, Poewe W, Wenning GK. Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. Mov Disord 2007; 22: 353-8. 

 

Stefanova N, Kollensperger M, Hainzer M, Cenci A, Poewe W, Wenning GK. High dose levodopa therapy is not toxic in multiple system atrophy: experimental evidence. Mov Disord 2007; 22: 969-73. 

 

Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 2006; 21: 179-86. 

 

Seppi K, Schocke MF, Prennschuetz-Schuetzenau K, Mair KJ, Esterhammer R, Kremser C, et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord 2006; 21: 847-52. 

 

Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK. Animal models of multiple system atrophy. Trends Neurosci 2005; 28: 501-6. 

 

Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord 2005; 20 Suppl 12: S67-76.

 

Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3: 93-103.

 

Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004; 19: 1391-402.